Searched for
COVID DRUG PRICE
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Why is the US stock market crashing today? S&P 500 erases all gains and wipes out $1.3 trillion in 2 hours as Nasdaq and Dow turn sharply lower - Tech stocks and chip sector collapseThe US stock market crash today caught many investors off guard. Early gains quickly vanished as the S&P 500 erased more than $1.3 trillion...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Strait of Hormuz is now India's biggest market risk, says Ashi AnandIndian markets await clarity on Strait of Hormuz shipping. Ashi Anand of IME Capital suggests a defensive market approach. Oil prices near ...
- Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiativeRegeneron will reduce prices for its drugs on Medicaid. A cholesterol drug, Praluent, will be available for USD 225 on Trump's discounted d...
- Iran war impact: Essential drugs may cost up to 5% more, for nowThe immediate net consumer impact could be 3-5% higher prices, or roughly similar to what consumers paid before the late-September cuts in ...
- Painkiller, antibiotic prices set for marginal increase starting April 1Starting April 1, the prices of essential medicines will experience an increase of 0.6%. This change aligns with the annual alterations in ...
- Reliance submits proposal for potential Covid drugNiclosamide, a drug on the World Health Organisation's list of essential medicines, has been used to treat tapeworm infestation for more th...
- DRDO's anti-COVID drug priced at Rs 990 per sachet; Centre, states to get discountsThe first batch of DRDO's anti-Covid-19 drug was released on May 17 by Defence Minister Rajnath Singh and health minister Dr Harsh Vardhan,...
- Remdesivir sells at 10x prices, NPPA unable to regulate as it's not notified as a 'drug'The NPPA can only control prices of devices and products that are defined as drugs under the Drugs and Cosmetics Act. A product or device t...
- Glenmark drops 5% as DCGI seeks clarity on Covid-19 drug, overpricing complaintsThe drug regulator also pulled up Glenmark over the pricing of the drug, after receiving a complaint from a member of Parliament.
- These are the companies manufacturing COVID-19 drug Remdesivir in India
- Will the launch of Favipiravir mark the turnaround for Glenmark Pharma?If the drug proves to be efficacious for Covid treatment, Glenmark will cash in on first mover advantage.
Load More
